Paper Details

  1. Home
  2. Paper Details

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.

Author: BerghöferP, ForbesA, GabeS M, HeinzeH, JeppesenP B, JolyF, LothS, MessingB, PertkiewiczM, PironiL, YoussefN N

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the effects of teduglutide, a glucagon-like peptide 2 analogue, on quality of life (QoL) in patients with short bowel syndrome (SBS)-intestinal failure (IF).
Paper Details　
Original Abstract of the Article :
Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clnu.2013.03.016

データ提供：米国国立医学図書館（NLM）

Teduglutide: A Promising Treatment for Short Bowel Syndrome

Short Bowel Syndrome (SBS) is a debilitating condition that can significantly impair quality of life. This study investigated the impact of a new treatment, teduglutide, on the quality of life of individuals with SBS.

A Glimpse of Hope: Teduglutide's Potential to Improve SBS

The research found that teduglutide, a glucagon-like peptide 2 analogue, demonstrated a positive impact on the quality of life of individuals with SBS. This is a significant finding, suggesting that teduglutide may offer a new therapeutic avenue for managing SBS and improving patient well-being. This discovery is akin to finding a hidden oasis in the desert—a source of respite and hope for individuals facing a challenging condition.

Navigating SBS: Seeking Personalized Solutions

Individuals with SBS often require a multifaceted approach to manage their condition. This may include dietary modifications, nutritional support, and medication. Teduglutide's potential to improve quality of life underscores the importance of consulting with a healthcare professional to develop a personalized treatment plan that addresses individual needs.

Dr. Camel's Conclusion

This research offers a beacon of hope for individuals struggling with SBS. Teduglutide's promising effects highlight the ongoing quest for new treatments that can alleviate the burden of this debilitating condition. It's like discovering a new path through the desert—a promising route toward a better quality of life for individuals with SBS.
Date :
  1. Date Completed 2014-04-16
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

23587733

DOI: Digital Object Identifier

10.1016/j.clnu.2013.03.016

Related Literature

Article Analysis
・Effects of teduglutide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.